VCBeat Health’s Post

Recently, the multi-center clinical registration trial of the first modular general microsurgical robot in China, sponsored by Guangzhou DeepSurgery Medical Instrument Technology Co.,Ltd, (hereafter referred to as “DeepSurgery”), has officially kicked off. Tigermed-Jyton is the selected CRO for this innovative and important study. The first patient enrollment in the country was completed today. This project marks a breakthrough from zero to one in the field of clinical registration studies for microsurgical robots in China and injects new impetus into the innovation of China domestic supreme medical equipment.  For the full news, please visit: https://lnkd.in/dBayZhuF

China NMPA Approves 348 Medical Devices in September 2025, Showcasing Regional Innovation Hubs Release Date: October 17, 2025 Issuing Authority: National Medical Products Administration (NMPA) In September 2025, China’s NMPA approved a total of 348 medical devices for market registration. This significant batch underscores the country's accelerating pace in medical technology innovation and regulatory advancement. Approval Breakdown: 276 Domestically Manufactured Class III Devices 34 Imported Class III Devices 36 Imported Class II Devices 2 Devices from Hong Kong, Macao, and Taiwan Regions Geographical Hotspots of Domestic Innovation: Analysis of the 276 domestic Class III approvals reveals strong regional clustering, with the top 5 regions accounting for over 60% of all approvals: 1.Jiangsu Province (61 approvals) – Leading the nation, with Suzhou as a standout hub for cardiovascular and orthopedic innovations. 2.Guangdong Province (44 approvals) – A powerhouse in Shenzhen (imaging, IVD, digital health) and Guangzhou. 3.Beijing (27 approvals) – Strong in high-value implants and AI-driven medical software. 4.Shanghai (18 approvals) – Excellence in cardiovascular tech and robotic surgery systems. 5.Zhejiang Province (15 approvals) – Growing influence in surgical consumables and minimally invasive devices. Key Product Categories Approved: The approved products represent a diverse and advanced portfolio, including: 1.Transcatheter Aortic Valve Systems 2.AI-Powered Diagnostic Imaging Software 3.Nucleic Acid Detection Kits (e.g., HIV, HPV, Influenza) 4.3D-Printed Spinal Implants and Artificial Vertebrae 5.Soft Hydrophilic Contact Lenses 6.High-Frequency Surgical Equipment 7.Robot-Assisted Surgical Navigation Systems 8.Absorbable Sutures and Anchor Implants 9.Dialysis and Infusion Systems Notable Companies with Approvals: Domestic Players: MicroPort, Mindray, Sinocare, Venus MedTech, SHINVA Global Innovators: Medtronic, Roche, Siemens Healthineers, Canon Medical, Karl Storz, Fresenius This approval wave highlights both the depth and breadth of China’s medtech evolution—from implantables and diagnostics to digital surgery—and reinforces the critical role of key innovation clusters in driving the industry forward. Full Official Announcement: https://lnkd.in/gZmSVftR #MedicalDevices #NMPA #RegulatoryAffairs #MedTech #HealthcareInnovation #ChinaFDA #MedicalTechnology #LifeSciences #IVD #SurgicalRobotics #DigitalHealth

China NMPA Approves 348 Medical Devices in September 2025, Showcasing Regional Innovation Hubs Release Date: October 17, 2025 Issuing Authority: National Medical Products Administration (NMPA) In September 2025, China’s NMPA approved a total of 348 medical devices for market registration. This significant batch underscores the country's accelerating pace in medical technology innovation and regulatory advancement. Approval Breakdown: 276 Domestically Manufactured Class III Devices 34 Imported Class III Devices 36 Imported Class II Devices 2 Devices from Hong Kong, Macao, and Taiwan Regions Geographical Hotspots of Domestic Innovation: Analysis of the 276 domestic Class III approvals reveals strong regional clustering, with the top 5 regions accounting for over 60% of all approvals: 1.Jiangsu Province (61 approvals) – Leading the nation, with Suzhou as a standout hub for cardiovascular and orthopedic innovations. 2.Guangdong Province (44 approvals) – A powerhouse in Shenzhen (imaging, IVD, digital health) and Guangzhou. 3.Beijing (27 approvals) – Strong in high-value implants and AI-driven medical software. 4.Shanghai (18 approvals) – Excellence in cardiovascular tech and robotic surgery systems. 5.Zhejiang Province (15 approvals) – Growing influence in surgical consumables and minimally invasive devices. Key Product Categories Approved: The approved products represent a diverse and advanced portfolio, including: 1.Transcatheter Aortic Valve Systems 2.AI-Powered Diagnostic Imaging Software 3.Nucleic Acid Detection Kits (e.g., HIV, HPV, Influenza) 4.3D-Printed Spinal Implants and Artificial Vertebrae 5.Soft Hydrophilic Contact Lenses 6.High-Frequency Surgical Equipment 7.Robot-Assisted Surgical Navigation Systems 8.Absorbable Sutures and Anchor Implants 9.Dialysis and Infusion Systems Notable Companies with Approvals: Domestic Players: MicroPort, Mindray, Sinocare, Venus MedTech, SHINVA Global Innovators: Medtronic, Roche, Siemens Healthineers, Canon Medical, Karl Storz, Fresenius This approval wave highlights both the depth and breadth of China’s medtech evolution—from implantables and diagnostics to digital surgery—and reinforces the critical role of key innovation clusters in driving the industry forward. Full Official Announcement: https://lnkd.in/gZmSVftR #MedicalDevices #NMPA #RegulatoryAffairs #MedTech #HealthcareInnovation #ChinaFDA #MedicalTechnology #LifeSciences #IVD #SurgicalRobotics #DigitalHealth

Percept Corporation is proud to announce that MiOptics™ therapeutic optics are now available to eye care professionals and patients across North America through our network of Authorized Qualified MiOptics Optical Labs. These include Cherry Optical, Complete Optical, OnSight Optical, Laramy-K, Pacific Artisan Labs and Plastic Plus — which also serves as our authorized Canadian distributor. By combining advanced optical engineering, clinical validation and the expertise of our lab partners, we’re helping redefine what’s possible in therapeutic optics for patients with chronic neurological conditions. Read the full article: https://lnkd.in/gNVZiQ2C

IOL approval news from Market Scope: Biotech Healthcare announced Sept. 23 that it had launched the #Optiflex #Xtense Comfort Plus extended-depth-of-focus (#EDOF) intraocular lens at The European Society of Cataract and Refractive Surgeons (ESCRS) 2025 congress in Copenhagen, Denmark. #IOL #EuropeNews #NowAvailable #cataract #surgical https://lnkd.in/gE9iqP-N

Glaucoma surgical device news from Market Scope: Iantrek announced Oct. 14 the US commercial launch of the #AlloFlo #Uveo, a novel minimally invasive glaucoma surgical (#MIGS) device targeting the uveoscleral drainage pathway. #glaucoma #surgical #NowAvailable https://lnkd.in/gPZdrpXi

With innovation heating up and access to eye care expanding, the global IOL market is on track for steady growth through 2032, DelveInsight Business Research LLP reports. From cutting-edge lens designs to next-gen personalized solutions, this sector is showing no signs of losing focus. Read all the details here: https://lnkd.in/dnYNWgeX #VisionInnovation #ophthalmologyNews #TechandPharma #MediaMICE #CAKEMagazine #IntraocularLens #IOL

We take great pride in working with more than 40 corporate members to advance Japan’s contribution to global healthcare. This time, we are pleased to feature Olympus Corporation, a global leader in medical technology. Celebrating its 106th anniversary this year, Olympus developed the world’s first practical gastrocamera in 1950. Since then, the company has advanced endoscopic technology in close collaboration with physicians, enhancing both diagnostic and therapeutic practices. Today, Olympus has grown into a company of approximately 30,000 employees across 40 countries, commanding roughly 70% of the global market share in gastrointestinal endoscopes. The company provides technologies and devices that support a wide range of fields from diagnosis to treatment and surgery while also driving product development, training, and academic exchange that reflect the voices of physicians and patients worldwide. Currently, in collaboration with MEJ, Olympus is also expanding its activities in Vietnam. Mr. Masao Kodama, General Director of Olympus Vietnam, shared his outlook: “Through MEJ’s public-private-academic-medical platform, we can go beyond the limits of what a single company can achieve. I look forward to Japan’s healthcare industry contributing as ‘Team Japan’ to the improvement of medical environments around the world.” --- MEJ企業メンバー Spotlight #2：Olympus Corporation MEJは、40社を超える企業会員の皆さまと共に日本の医療の国際展開に取り組めることに大いなるやりがいを感じています。今回は、グローバル・メドテックカンパニーであるオリンパス株式会社をご紹介。 本年、創立106周年を迎えたオリンパス。1950年に世界初の実用的な胃カメラを開発し、医師との二人三脚で内視鏡技術の改良を進め、診断や治療の進歩に貢献してきました。 今日、同社は世界40か国で約3万人を擁する企業へと成長し、消化器内視鏡では世界シェア約70%を誇っています。診断から治療・手術まで幅広い領域を支える技術やデバイスを提供。医師や患者の声を反映した製品開発やトレーニング、学術交流を世界各地で展開しています。 現在MEJと連携し、ベトナムでも活動を推進。Olympus Vietnamゼネラルダイレクター児玉壮生氏は次のように語ります。「MEJの産官学医プラットフォームにより、個社で取り組める限界を超え、日本の医療産業が“チーム・ジャパン”として世界の医療環境向上に貢献できることを期待しています。」 #Olympus #オリンパス #MedicalExcellenceJAPAN #MEJ #AdvancingGlobalHealthTogether #GlobalHealth

📢 Highlights of the Industrial News in the first 3 quarters 2025 in China 1.    TowardPi's OCT products maintained top position in both bid value and unit volume. Market share reached 38.7%, further extending their leading advantage👑. 2.    Joined ZEISS as the only two companies in the Chinese market to have all four of their major product lines rank within the top five in market share during the first three quarters🚀 . 3.    Five major milestones within one year including comprehensive report to the Premier Li Qiang🔉 . 4.    TowardPi announced the close of E+ funding round💰.  5.    The company's ophthalmic surgical microscopes, achieved the highest industry average selling price (ASP)💡 . https://lnkd.in/g3kTqXmY

📈 𝗙𝗼𝗿𝗲𝗰𝗮𝘀𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗚𝗹𝗼𝗯𝗮𝗹 𝗩𝗲𝗿𝘁𝗲𝗯𝗿𝗮𝗹 𝗗𝗶𝗹𝗮𝘁𝗶𝗼𝗻 𝗕𝗮𝗹𝗹𝗼𝗼𝗻 𝗖𝗮𝘁𝗵𝗲𝘁𝗲𝗿 𝗠𝗮𝗿𝗸𝗲𝘁 (𝟮𝟬𝟮𝟱–𝟮𝟬𝟯𝟭) The global 𝐯𝐞𝐫𝐭𝐞𝐛𝐫𝐚𝐥 𝐝𝐢𝐥𝐚𝐭𝐢𝐨𝐧 𝐛𝐚𝐥𝐥𝐨𝐨𝐧 𝐜𝐚𝐭𝐡𝐞𝐭𝐞𝐫 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐬 𝐩𝐨𝐢𝐬𝐞𝐝 𝐟𝐨𝐫 𝐬𝐢𝐠𝐧𝐢𝐟𝐢𝐜𝐚𝐧𝐭 𝐠𝐫𝐨𝐰𝐭𝐡 𝐛𝐞𝐭𝐰𝐞𝐞𝐧 𝟐𝟎𝟐𝟓 𝐚𝐧𝐝 𝟐𝟎𝟑𝟏. Driven by the rising prevalence of spinal disorders and the increasing adoption of minimally invasive procedures, the market is expected to expand substantially during this period. 🔍 𝗪𝗵𝘆 𝗜𝗻𝘃𝗲𝘀𝘁 𝗶𝗻 𝗧𝗵𝗶𝘀 𝗥𝗲𝗽𝗼𝗿𝘁? 👉Comprehensive Market Analysis: Gain insights into market size, growth trends, and forecasts from 2025 to 2031. 👉Competitive Landscape: Understand the strategies and market positions of key players like DePuy Synthes, Medtronic, and Stryker. 👉Regional Insights: Explore market dynamics across regions including North America, Europe, and Asia-Pacific. 👉Segmented Data: Detailed analysis by balloon size (10mm, 15mm, 20mm) and application (hospital, clinic). 👉Strategic Decision-Making: Equip stakeholders with data to make informed decisions in product development and market entry. 📊 𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗕𝘆 𝗧𝘆𝗽𝗲: 👉10mm 👉15mm 👉20mm 👉Others 𝗕𝘆 𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: 👉Hospital 👉Clinic 🌍 𝗥𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗠𝗮𝗿𝗸𝗲𝘁 𝗢𝘃𝗲𝗿𝘃𝗶𝗲𝘄 ✅United States: Leading in adoption due to advanced healthcare infrastructure. ✅China: Rapidly growing market driven by increasing healthcare investments. ✅Europe: Stable demand with a focus on technological advancements. ✅India: Emerging market with expanding healthcare access. 📈 𝗚𝗿𝗼𝘄𝘁𝗵 𝗗𝗿𝗶𝘃𝗲𝗿𝘀 👉Aging Population: Increased incidence of degenerative spine conditions. 👉Technological Advancements: Innovations leading to improved catheter designs. 👉Minimally Invasive Procedures: Preference for procedures offering reduced recovery times. 🏥 𝗞𝗲𝘆 𝗠𝗮𝗻𝘂𝗳𝗮𝗰𝘁𝘂𝗿𝗲𝗿𝘀: OrthoMidwest, representing DePuy Synthes, Medtronic, Stryker, Merit Medical Systems, Inc., Teknimed, Chongqing FWS Medical Device Co., Ltd., SUZHOU SUNAN ZIMMERED MEDICAL INSTRUMENT CO., LTD, Shanghai Kinetic Medical Co., Ltd. 𝗔𝘀𝗸 𝗳𝗼𝗿 𝗖𝘂𝘀𝘁𝗼𝗺𝗶𝘇𝗮𝘁𝗶𝗼𝗻 𝗼𝗿 𝗦𝘂𝗯𝗺𝗶𝘁 𝗬𝗼𝘂𝗿 𝗥𝗲𝗾𝘂𝗶𝗿𝗲𝗺𝗲𝗻𝘁 𝗛𝗲𝗿𝗲: https://lnkd.in/d8h9hjfm #VertebralDilationBalloonCatheter #MedicalDevices #SpinalHealth #MinimallyInvasiveSurgery #HealthcareInnovation #MarketForecast #MedicalTechnology #GlobalHealthcare #SpinalDisorders #InvestmentOpportunities